Mode
Text Size
Log in / Sign up
N/A N=21 Treatment

Neuromuscular Electrical Stimulation (NMES) in Patients With Intermittent Claudication

Intermittent Claudication · Peripheral Vascular Disease

Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcome: Primary: Change From Baseline in Initial Walking Distance — 64.3 metres

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Neuromuscular Electrical Stimulation (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Imperial College London
Primary completion
Oct 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Initial Walking Distance
64.3
PRIMARY
Absolute Walking Distance Measured by Treadmill
130
SECONDARY
Femoral Haemodynamics Measured by Femoral Artery Duplex Ultrasonography
SECONDARY
Laser Doppler Flow Measured by Optical Laser
SECONDARY
Symptomatic Scores by Questionnaire
SECONDARY
Quality of Life Scores Measured by Questionnaire
SECONDARY
Urine Metabolic Profile
SECONDARY
Serum Metabolic Profile

Summary

This study will assess the benefit of a neuromuscular electrical stimulation device in patients suffering from symptoms and effects of lower limb intermittent claudication.

Eligibility Criteria

Inclusion Criteria

  • All ethnic groups, male or female above the age of 18 years.
  • Diagnosis of mild intermittent claudication
  • Be of non-childbearing potential; OR using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the study device.
  • Blood pressure currently under moderate control ( 0.9
  • Has any metal implants
  • Pregnant
  • Has a cardiac pacemaker or defibrillator device
  • Has recent lower limb injury or lower back pain
  • Has current foot ulceration or other skin ulcers
  • Has foot deformities
  • Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02436200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search